Literature DB >> 30159950

Access to waitlisting for deceased donor kidney transplantation in Australia.

Matthew P Sypek1,2,3, Philip A Clayton1,4,5, Wai Lim6,7, Peter Hughes2,3, John Kanellis8, Jenni Wright9, Jeremy Chapman9,10, Stephen P McDonald1,4,5.   

Abstract

AIM: A detailed analysis of waitlisting for deceased donor kidney transplantation in Australia has not previously been reported. We aimed to determine if patient characteristics associated with waitlisting identify areas of potential inequality in access to transplantation in Australia.
METHODS: A competing risk time-to-event model was used to determine predictors of waitlisting for all adult incident renal replacement therapy patients in Australia between 2006 and 2015. Secondary analysis was performed to determine predictors of overall access to transplantation (using a combined outcome of waitlisting and living donor transplantation).
RESULTS: The cohort consisted of 21 231 patients with a median age of 63 years. Overall, 4361 (20.5%) were waitlisted and 1239 (5.8%) received a living donor transplant without being previously waitlisted. Primary analysis revealed that medical comorbidities, older age, smoking status and body mass index were all significant predictors of waitlisting and that and there was variation in waitlisting practice across states Despite adjustment for the above factors, demographic characteristics, including Indigenous ethnicity (subdistribution hazard ratios (SHR) 0.46 (95% confidence interval (CI) 0.38-0.55)), female gender (SHR 0.85 (95% CI 0.80, 0.91)) and residence in a regional area (SHR 0.88 (95% CI 0.81-0.95)) were also associated with a lower likelihood of waitlisting. Secondary analysis showed younger age and higher socio-economic advantage were additional predictors of overall access to transplantation, driven by higher rates of living donor transplantation.
CONCLUSION: Demographic as well as clinical characteristics are associated with reduced likelihood of waitlisting for kidney transplantation in Australia. Further analysis and auditing should be considered to determine if this reflects other unmeasured factors or highlights a need to address inequality.
© 2018 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  access; equity; kidney transplant; waitlist

Year:  2019        PMID: 30159950     DOI: 10.1111/nep.13484

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  4 in total

1.  Modest rates and wide variation in timely access to repeat kidney transplantation in the United States.

Authors:  Jesse D Schold; Joshua J Augustine; Anne M Huml; John O'Toole; John R Sedor; Emilio D Poggio
Journal:  Am J Transplant       Date:  2019-11-15       Impact factor: 8.086

2.  Weight change trajectories in Aboriginal and Torres Strait islander Australians after kidney transplantation: a cohort analysis using the Australia and New Zealand Dialysis and Transplant registry (ANZDATA).

Authors:  Sandawana William Majoni; Shahid Ullah; James Collett; Jaquelyne T Hughes; Stephen McDonald
Journal:  BMC Nephrol       Date:  2019-06-25       Impact factor: 2.388

3.  Sex Differences in Kidney Transplantation: Austria and the United States, 1978-2018.

Authors:  Sebastian Hödlmoser; Teresa Gehrig; Marlies Antlanger; Amelie Kurnikowski; Michał Lewandowski; Simon Krenn; Jarcy Zee; Roberto Pecoits-Filho; Reinhard Kramar; Juan Jesus Carrero; Kitty J Jager; Allison Tong; Friedrich K Port; Martin Posch; Wolfgang C Winkelmayer; Eva Schernhammer; Manfred Hecking; Robin Ristl
Journal:  Front Med (Lausanne)       Date:  2022-01-24

4.  AcceSS and Equity in Transplantation (ASSET) New Zealand: Protocol for population-wide data linkage platform to investigate equity in access to kidney failure health services in New Zealand.

Authors:  Rachel B Cutting; Angela C Webster; Nicholas B Cross; Heather Dunckley; Ben Beaglehole; Ian Dittmer; John Irvine; Curtis Walker; Merryn Jones; Melanie Wyld; Patrick J Kelly; Kate Wyburn; Nicole L De La Mata
Journal:  PLoS One       Date:  2022-08-25       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.